Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

467 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.
Lennerz JK, Kwak EL, Ackerman A, Michael M, Fox SB, Bergethon K, Lauwers GY, Christensen JG, Wilner KD, Haber DA, Salgia R, Bang YJ, Clark JW, Solomon BJ, Iafrate AJ. Lennerz JK, et al. Among authors: lauwers gy. J Clin Oncol. 2011 Dec 20;29(36):4803-10. doi: 10.1200/JCO.2011.35.4928. Epub 2011 Oct 31. J Clin Oncol. 2011. PMID: 22042947 Free PMC article. Clinical Trial.
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.
Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK. Willett CG, et al. Among authors: lauwers gy. Nat Med. 2004 Feb;10(2):145-7. doi: 10.1038/nm988. Epub 2004 Jan 25. Nat Med. 2004. PMID: 14745444 Free PMC article. Clinical Trial.
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.
Willett CG, Boucher Y, Duda DG, di Tomaso E, Munn LL, Tong RT, Kozin SV, Petit L, Jain RK, Chung DC, Sahani DV, Kalva SP, Cohen KS, Scadden DT, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Shellito PC, Mino-Kenudson M, Lauwers GY. Willett CG, et al. Among authors: lauwers gy. J Clin Oncol. 2005 Nov 1;23(31):8136-9. doi: 10.1200/JCO.2005.02.5635. J Clin Oncol. 2005. PMID: 16258121 Clinical Trial. No abstract available.
Pancreatoblastoma in a teenage patient.
Bendell JC, Lauwers GY, Willett C, Clark JW, Warshaw AL, Wain JC, Ryan DP. Bendell JC, et al. Among authors: lauwers gy. Clin Adv Hematol Oncol. 2006 Feb;4(2):150-3; discussion 154. Clin Adv Hematol Oncol. 2006. PMID: 16728924 No abstract available.
Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas.
Kwak EL, Jankowski J, Thayer SP, Lauwers GY, Brannigan BW, Harris PL, Okimoto RA, Haserlat SM, Driscoll DR, Ferry D, Muir B, Settleman J, Fuchs CS, Kulke MH, Ryan DP, Clark JW, Sgroi DC, Haber DA, Bell DW. Kwak EL, et al. Among authors: lauwers gy. Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4283-7. doi: 10.1158/1078-0432.CCR-06-0189. Clin Cancer Res. 2006. PMID: 16857803 Free PMC article.
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study.
Willett CG, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Sahani DV, Lahdenranta J, Chung DC, Fischman AJ, Lauwers GY, Shellito P, Czito BG, Wong TZ, Paulson E, Poleski M, Vujaskovic Z, Bentley R, Chen HX, Clark JW, Jain RK. Willett CG, et al. Among authors: lauwers gy. J Clin Oncol. 2009 Jun 20;27(18):3020-6. doi: 10.1200/JCO.2008.21.1771. Epub 2009 May 26. J Clin Oncol. 2009. PMID: 19470921 Free PMC article. Clinical Trial.
467 results